Itafos Inc. (TSX-V: IFOS) (the “Company”) reported today its Q2 and
H1 2021 financial and operational highlights. The Company’s
financial statements and management’s discussion and analysis for
the three and six months ended June 30, 2021 are available under
the Company’s profile at www.sedar.com and on the Company’s website
at www.itafos.com. All figures are unaudited in thousands of US
Dollars except as otherwise noted.
The Company also announced today that it has closed a three-year
$205 million secured term loan (the “Term Loan”). The proceeds of
the Term Loan were used to repay the Company’s existing secured
term credit facility (the “Credit Facility”) and to pay related
transaction costs and fees. In connection with the closing of the
Term Loan, the Company also completed an amendment to its existing
secured working capital facility at Conda (the “Conda ABL”) to
increase the commitment amount from $20 million to $40 million and
extend the term, among other modifications as detailed below. Also
in connection with the closing of the Term Loan, the Company
completed an amendment to its existing unsecured and subordinated
promissory note (the “Promissory Note”) to cancel the remaining
availability and extend the term, among other modifications as
detailed below.
Q2 and H1 2021 Market Highlights
DAP NOLA prices averaged $570/st in Q2 2021
compared to $270/st in Q2 2020, up 111% year-over-year driven by
strong agriculture and phosphate fertilizer market supply and
demand dynamics. Similarly, DAP NOLA prices averaged $537/st in H1
2021 compared to $271/st in H1 2020, up 98% year-over-year.
Specific factors driving the year-over-year improvements were as
follows:
- no significant phosphate fertilizer supply capacity additions,
which resulted in continued drawdown of global phosphate fertilizer
inventory levels;
- strong phosphate fertilizer demand
underpinned by global coarse grains and oilseeds at multi-year low
stocks-to-use ratios and the highest prices in nearly a decade,
supporting demand and fertilizer relative affordability; and
- CVD orders confirmed by the US ITC
on phosphate fertilizer imports to the US from Morocco and
Russia.
Q2 2021 Financial Highlights
The Company’s revenues, adjusted EBITDA, net income
and free cash flow were all up in Q2 2021 compared to Q2 2020 as
follows:
- revenues of $103.3 million in Q2 2021
compared to $62.1 million in Q2 2020;
- adjusted EBITDA of $33.7 million in Q2
2021 compared to $11.3 million in Q2 2020;
- net income of $9.6 million in Q2 2021
compared to $(20.8) million in Q2 2020; and
- free cash flow of $25.4 million in Q2
2021 compared to $0.4 million in Q2 2020.
The Company’s total capex spend in Q2 2021 was $18.2 million
compared to $3.0 million in Q2 2020 with the increase reflecting
the completion of a full scope turnaround at Conda during June 2021
compared to a reduced scope turnaround in 2020.
H1 2021 Financial Highlights
The Company’s revenues, adjusted EBITDA, net income
and free cash flow were all up in H1 2021 compared to H1 2020 as
follows:
- revenues of $193.5 million in H1 2021
compared to $137.5 million in H1 2020;
- adjusted EBITDA of $54.3 million in H1
2021 compared to $10.5 million in H1 2020;
- net income of $11.5 million in H1 2021
compared to $(39.1) million in H1 2020; and
- free cash flow of $40.1 million in H1
2021 compared to $(7.5) million in H1 2020.
The Company’s total capex spend in H1 2021 was $21.0 million
compared to $6.4 million in H1 2020 with the increase reflecting
the completion of a full scope turnaround at Conda during June 2021
compared to a reduced scope turnaround in 2020.
June 30, 2021 Net Debt and Liquidity
Highlights
As at June 30, 2021, the Company had net debt of $213.8 million
compared to $233.9 million at the end of 2020 with the decrease
primarily a result of higher cash and cash equivalents, which was
partially offset by in-kind interest related to the Credit Facility
and Promissory Note. The Company’s net debt as at June 30, 2021 was
comprised of $34.9 million in cash and $248.6 million in debt.
As at June 30, 2021, the Company had liquidity of $42.3
million comprised of $34.9 million in cash, $5.4 million in
Promissory Note undrawn borrowing base and $2.0 million in Conda
ABL undrawn borrowing base.
Q2 2021 Operational Highlights
EHS
- continued corporate-wide risk
mitigation measures to address potential impacts to employees,
contractors and operations as a result of the COVID-19 pandemic
resulting in no material impact on operations; and
- sustained environmental, health and
safety (“EHS”) excellence, including no reportable environmental
releases and one recordable incident, which resulted in a
consolidated TRIFR of 0.84.
Conda
- completed a full scope plant turnaround at Conda during June
2021, including certain activities that had been deferred following
the Company’s decision to conduct a reduced scope plant turnaround
in 2020 as part of Company’s COVID-19 risk mitigation
measures;
- produced 107,517 tonnes in Q2 2021
compared to 134,391 tonnes in Q2 2020, down 20% year-over-year
primarily due to a full scope turnaround at Conda during June
2021;
- generated revenues of $103,316 in Q2
2021 compared to $61,948 in Q2 2020 with the increase primarily due
to higher realized prices and higher sales volumes;
- generated adjusted EBITDA at Conda of
$37,705 in Q2 2021 compared to $14,458 in Q2 2020 with the increase
primarily due to higher realized prices and higher sales volumes,
which were partially offset by higher input costs;
- recorded net income at Conda of
$24,370 in Q2 2021 compared to $3,428 in Q2 2020 with the increase
primarily due to the same factors that resulted in higher adjusted
EBITDA and lower depreciation and depletion, which were partially
offset by higher finance and income tax expenses;
- completed a full scope plant
turnaround, including certain activities that had been deferred
following the Company’s decision to conduct a reduced scope plant
turnaround in 2020 as part of Company’s COVID-19 risk mitigation
measures;
- advanced activities related to the
extension of Conda’s mine life through permitting and development
of H1/NDR, including progression of the NEPA EIS preparation and
public engagement process;
- advanced activities related to the
optimization of Conda’s EBITDA generation, including:
- continuation of the ramp up of MAP+
production and sales volumes,
- advancement of initiative to produce
and sell HFSA, including advancement of detailed engineering,
design and procurement and advancement of a potential offtake
agreement; and
- advancement of test work related to
the MgO reduction initiative to enhance SPA production and sales
volumes.
Other Segments
- maintained the idling of Arraias
following best practices;
- maintained Farim at construction ready
state while optimizing costs; and
- continued corporate-wide cost savings
initiatives.
H1 2021 Operational Highlights
EHS
- continued corporate-wide risk
mitigation measures to address potential impacts to employees,
contractors and operations as a result of the COVID-19 pandemic
resulting in no material impact on operations; and
- sustained EHS excellence, including no
reportable environmental releases and two recordable incidents,
which resulted in a consolidated TRIFR of 0.84.
Conda
- completed a full scope plant turnaround at Conda during June
2021, including certain activities that had been deferred following
the Company’s decision to conduct a reduced scope plant turnaround
in 2020 as part of Company’s COVID-19 risk mitigation
measures;
- produced 252,708 tonnes in H1 2021
compared to 273,287 tonnes in H1 2020, down 7.5% year-over-year
primarily due to a full scope plant turnaround during June
2021;
- generated revenues of $193,458 in H1
2021 compared to $132,880 in H1 2020 with the increase primarily
due to higher realized prices, which were partially offset by lower
sales volumes;
- generated adjusted EBITDA at Conda of
$61,869 in H1 2021 compared to $22,753 in H1 2020 with the increase
primarily due to higher realized prices, which were partially
offset by lower sales volumes and higher input costs;
- recorded net income at Conda of
$39,134 in H1 2021 compared to $4,383 in H1 2020 with the increase
primarily due to the same factors that resulted in higher adjusted
EBITDA and lower depreciation and depletion, which were partially
offset by higher finance and income tax expenses;
- completed a full scope plant
turnaround, including certain activities that had been deferred
following the Company’s decision to conduct a reduced scope plant
turnaround in 2020 as part of Company’s COVID-19 risk mitigation
measures;
- advanced activities related to the
extension of Conda’s mine life through permitting and development
of H1/NDR, including progression of the NEPA EIS preparation and
public engagement process;
- advanced activities related to the
optimization of Conda’s EBITDA generation, including:
- continuation of the ramp up of MAP+
production and sales volumes,
- advancement of initiative to produce
and sell HFSA, including completion of a concept study, advancement
of detailed engineering, design and procurement and advancement of
a potential offtake agreement; and
- advancement of test work related to
the MgO reduction initiative to enhance SPA production and sales
volumes.
Other Segments
- maintained the idling of Arraias
following best practices;
- maintained Farim at construction ready
state while optimizing costs; and
- continued corporate-wide cost savings
initiatives.
Subsequent Events
Redomiciliation
On July 1, 2021, the Company completed a
redomiciliation from the Cayman Islands to the US. The
redomiciliation was implemented as a continuation of the Company’s
jurisdiction of incorporation from the Cayman Islands to the State
of Delaware. In connection with the redomiciliation, the Company
changed its name from Itafos to Itafos Inc.
Refinancing
On August 25, 2021, the Company closed the Term
Loan. The proceeds of the Term Loan were used to repay the Credit
Facility and to pay related transaction costs and fees. In
connection with the closing of the Term Loan, the Company also
completed an amendment to the Conda ABL to increase the commitment
amount from $20 million to $40 million and extend the term, among
other modifications as detailed below. Also in connection with the
closing of the Term Loan, the Company completed an amendment to the
Promissory Note to cancel the remaining availability and extend the
term, among other modifications as detailed below.
Term Loan
The key terms of the Term Loan are as follows:
- principal amount of $205 million;
- term of three years;
- interest rate of 8.25% per annum plus the London Interbank
Offered Rate (“LIBOR”), subject to a floor of 1.00%, with interest
payments payable in cash on a quarterly basis;
- amortization of 15% per annum with principal payments payable
on a quarterly basis and a one-time principal payment on or before
15 months after the closing date in an amount sufficient to reduce
the outstanding principal balance to $155 million or less; and
- other terms, financial covenants, fees and cost reimbursements
standard and customary for similar agreements.
Lenders to the Term Loan include a syndicate of lenders
comprised of certain funds and accounts managed by Oaktree Capital
Management, L.P. The guarantors to the Term Loan include various
subsidiaries of the Company (the “Guarantors”). The Term Loan is
secured by all assets of the Company and the Guarantors.
Amendment to Conda ABL
The key terms of the amendment to the Conda ABL are as
follows:
- commitment size increased from $20 million to $ 40
million;
- term extended from August 7, 2023 to the earlier of August 25,
2024 and 91 days before the maturity of the Term Loan (if the Term
Loan is outstanding on such date);
- collateral expanded from accounts receivable, inventory and
cash pledged by Conda to include a second lien on all other assets
of the Company and the Guarantors; and
- other modifications to conform terms and conditions with the
Term Loan.
The Company’s wholly owned subsidiary, Itafos Conda LLC,
originally entered into the Conda ABL with JPMorgan Chase on August
7, 2020. Other key terms of the Conda ABL, including the interest
rate, were not amended.
Amendment to Promissory Note
The key terms of the amendment to the Promissory Note are as
follows:
- commitment amount reduced from $36.0 million to $30.6 million,
which cancelled the previously remaining availability of $5.4
million;
- term extended from payable on demand no earlier than six months
after the date on which the Credit Facility is paid in full to
payable on demand after the later of (i) August 25, 2024 or (ii)
six months after the date on which the Term Loan and the Conda ABL
are paid in full and commitments under the Conda ABL are
terminated; however, if the obligations under the Term Loan and the
Conda ABL are accelerated, then the Promissory Note would become
payable on demand;
- interest rate per annum increased from 15% to 18% starting on
August 25, 2022 if the Company has not repaid at least $20 million
under the Promissory Note by such date;
- amendment fee of 4% of the principal amount payable in kind at
closing;
- exit fee of 4% payable in cash upon any payment of principal;
and
- other terms and cost reimbursements standard and customary for
similar agreements.
The Company originally entered into the Promissory Note with CL
Fertilizers Holding LLC (“CLF”) on September 11, 2019, which was
subsequently amended and restated on December 31, 2019.
CLF is a “related party” to the Company under Multilateral
Instrument 61-101 – Protection of Minority Security Holders in
Special Transactions (“MI 61-101”) by virtue of its shareholding
being in excess of 10% of the Company’s issued and outstanding
share capital. Accordingly, the entering into of the amendment to
the Promissory Note constitutes a “related party transaction” under
MI 61-101. The transaction is exempt from (i) the formal valuation
requirements under Section 5.4 of MI 61-101 pursuant to Subsection
5.5(b) of MI 61-101; and (ii) the minority approval requirements
under Section 5.6 of MI 61-101 pursuant to Subsections 5.7(1)(a)
and 5.7(1)(f).
Market Outlook
The Company expects the current global agriculture
and phosphate fertilizer fundamentals to remain strong throughout
the remainder of 2021. Accordingly, the Company has increased its
previously provided adjusted EBITDA and free cash flow guidance for
H2 and FY 2021 (see Financial Guidance below).
Specific factors the Company expects to influence
the phosphate fertilizer markets are as follows:
- no significant phosphate fertilizer
supply capacity additions in 2021 due to voluntary postponement of
project schedules in recent years and delays related to the
COVID-19 pandemic, resulting in continued drawdown of global
phosphate fertilizer inventory levels;
- continued strong phosphate fertilizer
demand underpinned by global coarse grains and oilseeds reaching
multi-year low stocks-to-use ratios and the highest prices in
nearly a decade, the effects of which are expected to continue
beyond the current growing season; and
- continued strong pricing and volume
fundamentals in the North American phosphate fertilizer markets
reflecting the solid demand fundamentals, depleted inventory levels
and higher crop prices.
Financial Guidance
The Company has revised its guidance for 2021 as
follows:
|
|
Actual |
|
|
Projected |
|
|
Projected |
(in millions of US Dollars) |
|
H1 2021 |
|
|
H2 2021 |
|
|
FY 2021 |
Adjusted EBITDA |
$ |
54 |
|
$ |
55-65 |
|
$ |
110-120 |
Maintenance capex |
|
17 |
|
|
5-8 |
|
|
22-25 |
Growth capex |
|
4 |
|
|
8-11 |
|
|
12-15 |
Free cash flow |
|
40 |
|
|
15-25 |
|
|
55-65 |
The Company’s revised guidance for FY 2021 is
explained as follows:
- increased adjusted EBITDA guidance to $110-120 million
(previously $95-105 million) to reflect the Company’s view of
expected higher H2 2021 prices at Conda, including the current DAP
NOLA prices (100% of Conda’s MAP is sold under a long-term offtake
agreement with pricing indexed to DAP NOLA on an average
three-month trailing basis) and higher prices for SPA;
- tightened maintenance capex guidance
to $22-25 million (previously $20-25 million);
- tightened growth capex guidance to
$12-15 million (previously $12-17 million); and
- increased free cash flow guidance to $55-65 million (previously
$40-50 million) to reflect the increase in adjusted EBITDA guidance
and improved efficiencies in corporate structure following
completion of the Company’s redomiciliation from the Cayman Islands
to the US, which are expected to be partially offset by higher
expected H2 2021 working capital requirements.
Business Outlook
The Company continues to execute on its strategy, which is
focused on the following:
- extending Conda’s current mine life through permitting and
development of H1/NDR;
- optimizing Conda’s EBITDA generation;
- maintaining the idling of Arraias following best practices
while evaluating strategic alternatives;
- maintaining Farim at construction ready state while evaluating
strategic alternatives;
- maintaining the integrity of the concessions of Santana and
Araxá while evaluating strategic alternatives;
- advancing the wind down of Paris Hills and Mantaro; and
- continuing corporate-wide cost savings initiatives.
About Itafos
The Company is a phosphate and specialty
fertilizer company.
The Company’s businesses and projects are as
follows:
- Conda – a vertically integrated
phosphate fertilizer business with production capacity of
approximately 550kt per year of monoammonium phosphate (“MAP”), MAP
with micronutrients (“MAP+”), superphosphoric acid (“SPA”),
merchant grade phosphoric acid (“MGA”) and ammonium polyphosphate
(“APP”) located in Idaho, US;
- Arraias – a vertically integrated
phosphate fertilizer business with production capacity of
approximately 500kt per year of single superphosphate (“SSP”), SSP
with micronutrients (“SSP+”) and approximately 40kt per year of
excess sulfuric acid located in Tocantins, Brazil;
- Farim – a high-grade phosphate mine
project located in Farim, Guinea-Bissau;
- Santana – a vertically integrated
high-grade phosphate mine and fertilizer plant project located in
Pará, Brazil;
- Araxá – a vertically integrated
rare earth elements and niobium mine and extraction plant project
located in Minas Gerais, Brazil;
- Paris Hills – a phosphate mine
project located in Idaho, US (wind down in process); and
- Mantaro – a phosphate mine project
located in Junin, Peru (wind down in process).
The Company is a Delaware corporation that is headquartered in
Houston, TX. The Company’s shares trade on the TSX Venture Exchange
(“TSX-V”) under the ticker symbol “IFOS”. The Company’s principal
shareholder is CLF. CLF is an affiliate of Castlelake, L.P., a
global private investment firm.
For more information, or to join the Company’s mailing list to
receive notification of future news releases, please visit the
Company’s website at www.itafos.com.
Non-IFRS Financial Measures
The Company considers both IFRS and certain non-IFRS measures to
assess performance. Non-IFRS measures are a numerical measure of a
company’s performance, that either include or exclude amounts that
are not normally included or excluded from the most directly
comparable IFRS measures. In evaluating non-IFRS measures,
investors, analysts, lenders and others should consider that
non-IFRS measures do not have any standardized meaning under IFRS
and that the methodology applied by the Company in calculating such
non-IFRS measures may differ among companies and analysts. The
Company believes the non-IFRS measures provide useful supplemental
information to investors, analysts, lenders and others in order to
evaluate the Company’s operational and financial performance. These
non-IFRS financial measures should not be considered as a
substitute for, nor superior to, measures of financial performance
prepared in accordance with IFRS.
Non-IFRS measures included in this news release are defined as
follows:
- “EBITDA” as earnings before interest, taxes, depreciation,
depletion and amortization;
- “Adjusted EBITDA” as EBITDA adjusted for non-cash,
extraordinary, non-recurring and other items unrelated to the
Company’s core operating activities;
- “Total capex” as additions to property, plant, and equipment
and mineral properties adjusted for additions to asset retirement
obligations, additions to right of use assets, capitalized interest
and technical studies;
- “Maintenance capex” as portion of total capex relating to the
maintenance of ongoing operations;
- “Growth capex” as portion of total capex relating to
development of growth opportunities;
- “Cash growth capex” as growth capex less accrued growth
capex;
- “Free cash flow” as cash flows from operating activities, which
excludes payment of interest expense, plus cash flows from
investing activities less cash growth capex;
- “Net debt” as debt less cash and cash equivalents plus deferred
financing costs; and
- “Liquidity” as cash and cash equivalents plus undrawn committed
borrowing capacity.
Reconciliations of non-IFRS measures to the most directly
comparable IFRS measures are included in the Company’s management’s
discussion and analysis available under the Company’s profile
at www.sedar.com and on the Company’s website at
www.itafos.com.
Other Defined Terms
Other defined terms included in this news release are as
follows:
- Coronavirus disease 2019 (“COVID-19”);
- Countervailing duty (“CVD”);
- Diammonium phosphate (“DAP”) New Orleans (“NOLA”); and
- Environmental, Health and Safety (“EHS”)
- Environmental Impact Statement (“EIS”);
- Husky 1/North Dry Ridge (“H1/NDR”);
- Hydrofluorosilicic acid (“HFSA”);
- International Trade Commission (“ITC”);
- Magnesium oxide (“MgO”);
- National Environmental Policy Act (“NEPA”);
- Total recordable incident frequency rate (“TRIFR”).
Forward-Looking Information
Certain information contained in this news release constitutes
forward-looking information. All information other than information
of historical fact is forward-looking information. Statements that
address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future
include, but are not limited to, statements regarding estimates
and/or assumptions in respect of the Company’s financial and
business outlook and statements regarding the closing of the Term
Loan, the repayment of the Credit Facility; the amendment to the
Conda ABL and the amendment to the Promissory Note. The use of any
of the words “intend”, “anticipate”, “plan”, “continue”,
“estimate”, “expect”, “may”, “will”, “project”, “should”, “would”,
“believe”, “predict” and “potential” and similar expressions are
intended to identify forward-looking information. This information
involves known and unknown risks, uncertainties and other factors
that may cause actual results or events to differ materially from
those anticipated in such forward-looking information. No assurance
can be given that this information will prove to be correct and
such forward-looking information included in this news release
should not be unduly relied upon.
Forward-looking information is subject to a number of risks and
other factors that could cause actual results and events to vary
materially from that anticipated by such forward-looking
information. Although the Company has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking statements,
there may be other factors that cause results not to be as
anticipated, estimated or intended. Factors that may cause actual
results to differ materially from expected results described in
forward-looking statements include, but are not limited to, the
duration and spread of the COVID-19 pandemic and its severity;
uncertainties of estimates of capital and operating costs and
production estimates; the ability of the Company to meet its
financial obligations and minimum commitments, fund capital
expenditures and comply with covenants contained in the agreements
that govern indebtedness; the Company’s ability to advance capital
raising objectives; fluctuations in foreign exchange or interest
rates and stock market volatility; the continued supply of sulfuric
acid supply at Conda from its primary supplier and those risk
factors set out in the Company’s management discussion and analysis
and other disclosure documents available under the Company’s
profile at www.sedar.com and on the Company’s website at
www.itafos.com. Readers are cautioned that the foregoing list of
risks, uncertainties and assumptions are not exhaustive. The
forward-looking information included in this news release is
expressly qualified by this cautionary statement and is made as of
the date of this news release. The Company undertakes no obligation
to publicly update or revise any forward-looking information except
as required by applicable securities laws.
This news release contains future oriented financial information
and financial outlook information (together, “FOFI”) about the
Company’s prospective results of operations, including statements
regarding expected adjusted EBITDA, maintenance capex, growth capex
and free cash flow. FOFI is subject to the same assumptions, risk
factors, limitations and qualifications as set forth in the above
paragraph. The Company has included the FOFI to provide an outlook
of management’s expectations regarding anticipated activities and
results, and such information may not be appropriate for other
purposes. The Company and management believe that the FOFI has been
prepared on a reasonable basis, reflecting management’s reasonable
estimates and judgements; however, actual results of operations and
the resulting financial results may vary from the amounts set forth
herein. Any financial outlook information speaks only as of the
date on which it is made and the Company undertakes no obligation
to publicly update or revise any financial outlook information
except as required by applicable securities laws.
NEITHER THE TSX-V NOR ITS REGULATION SERVICES PROVIDER (AS THAT
TERM IS DEFINED IN THE POLICIES OF THE TSX-V) ACCEPTS
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS
RELEASE.
For further information, please contact:
Itafos Investor Relationsinvestor@itafos.comwww.itafos.com
Itafos (TSXV:IFOS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Itafos (TSXV:IFOS)
Historical Stock Chart
From Dec 2023 to Dec 2024